Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ALEC vs AKRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ALEC Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–4 Matrix Metrics)

ALEC Overall Winner 6-Pillar Tally: ALEC 6 – 0 AKRO Matrix Metrics: ALEC 6 – 4 AKRO

As of Nov 20, 2026, Alector, Inc. (ALEC) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ALEC carries a Unified Composite Score of 52.1/100 (HOLD) at $2.33 (8.5x Forward P/E, 21.8% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. ALEC 52.1/100 HOLD), ALEC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (21.8% vs. 0.0% operating margin) and revenue trajectory (+4895.9% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ALEC vs AKRO
ALEC NASDAQ Head-to-Head Winner
Alector, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$2.33
+1.52% 1D
Market Cap $342.4M
TTM Revenue $173M
Forward P/E 8.5x
Beta / 30D Vol 1.53β · 98% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 39.0 Fund 52.0 Flow 72.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $2.32 · SMA50: $2.09
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91

6-Pillar Scorecard Institutional Category Breakdown (ALEC 6 – 0 AKRO)

Columns: Metric · ALEC · AKRO
1. Valuation Multiples ALEC
Forward P/E 8.5x N/M
Trailing P/E 6.2x N/M
PEG Ratio N/M N/M
EV / Revenue 1.7x N/M
2. Growth & Scale ALEC
Revenue Growth (YoY) +4895.9% +0.0%
Earnings Growth (YoY) -86.3% +0.0%
TTM Revenue (USD) $173M N/A
Market Cap $342.4M $4.5B
3. Profitability & Quality ALEC
Gross Margin 42.5% N/A
Operating Margin 21.8% 0.0%
Net Profit Margin 23.9% 0.0%
Return on Equity (ROE) 47.5% -34.5%
4. Balance Sheet & Cash Flow ALEC
Cash Generation (TTM) -$150M N/A
Cash Flow Margin -86.5% N/A
Net Cash / Leverage $54M Net Cash $11.95 Book/Sh · -34.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ALEC
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 152.6% (18th %ile) 7.3% (30th %ile)
Put/Call OI Skew 0.06x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat ALEC
OpEx & R&D Intensity 20.7% of Rev ($36M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ALEC (6) vs AKRO (4)
Institutional Metric ALEC AKRO Criterion Row Edge
Market Capitalization
Scale
$342.4M $4.5B Larger Scale AKRO
Trailing P/E Ratio
Valuation
6.2x N/M Lower Multiple ALEC
Forward P/E Ratio
Valuation
8.5x N/M Lower Multiple ALEC
Revenue Growth (YoY)
Growth
+4895.9% +0.0% Higher Growth ALEC
Operating Margin (TTM)
Profitability
21.8% 0.0% Higher Margin ALEC
Net Profit Margin
Profitability
23.9% 0.0% Higher Margin ALEC
Return on Equity (ROE)
Capital Efficiency
47.5% -34.5% Higher ROE ALEC
52-Week Range Position
Momentum
71% ($1–$3) 90% ($21–$58) Stronger Trend AKRO
Beta / 30D Volatility
Risk Regime
1.53β · 98% Vol 0.90β · 2% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 60.0 / 100 (BUY) Higher Composite AKRO
Trailing 12M Revenue (USD)
Operating Scale
$173M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
42.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($54M Net Cash) N/A ($11.95 Book/Sh · -34.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AKRO +0.57 pp
ALEC: +0.0% · AKRO: +0.57%
3M Horizon AKRO +0.57 pp
ALEC: +0.0% · AKRO: +0.57%
6M Horizon AKRO +0.57 pp
ALEC: +0.0% · AKRO: +0.57%
1Y Horizon AKRO +0.57 pp
ALEC: +0.0% · AKRO: +0.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ALEC vs AKRO. Trailing 12-month operating profitability (ALEC 21.8% vs AKRO 0.0%) and valuation multiples (ALEC 8.5x vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ALEC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$173M
Gross Margin42.5%
Op. Margin21.8%
ROE / Fwd P/E47.5% · 8.5x
AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ALEC CONSOLIDATION
56d in phase · OBV NEUTRAL
Current IV 152.6%
IV Percentile 18th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ALEC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ALEC Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $342.4M market capitalization and 21.8% operating margin.
OpEx & R&D Reinvestment 20.7% of Rev ($36M)
90D Engineering Disclosures 0 Published
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ALEC vs AKRO Key Questions & Quantitative Answers

As of Nov 20, 2026, Alector, Inc. (ALEC) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ALEC carries a Unified Composite Score of 52.1/100 (HOLD) at $2.33 (8.5x Forward P/E, 21.8% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. ALEC 52.1/100 HOLD), ALEC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (21.8% vs. 0.0% operating margin) and revenue trajectory (+4895.9% vs. +0.0% YoY).

ALEC leads the Growth & Scale pillar: ALEC posts +4895.9% YoY revenue growth and -86.3% YoY earnings growth on $173M TTM revenue (42.5% gross margin, 21.8% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ALEC generates $173M in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, ALEC deploys 20.7% of Rev ($36M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.

ALEC screens cheaper on headline valuation multiples. ALEC trades at 8.5x Forward P/E, 6.2x Trailing P/E, N/M PEG, and 1.7x EV/Revenue (-86.5% FCF margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALEC (47.5% ROE) versus AKRO (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ALEC carries 152.6% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.53β · 98% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.